PNAS Science Sessions Podcast
Summary: Science Sessions is the podcast program of Proceedings of the National Academy of Sciences (PNAS). Listen to brief conversations with cutting-edge researchers, National Academy of Sciences members, and policy makers as they discuss topics relevant to today's scientific community. Learn the behind-the-scenes story of research published in PNAS, plus a broad range of science news and discoveries that affect the world around us.
Chemical biologist Allan Conney discusses his research on caffeine's anticancer properties.
Neuroscientist Charles F. Stevens discusses his research on finding the brain's underlying design principles.
Marc Kirschner discusses the goals of systems pharmacology.
Frances Arnold explains how she harnesses the power of evolution to create proteins and organisms with applications in medicine and in alternative energy.
Akiko Iwasaki explains how gut bacteria boost immunity to influenza virus.
Sarkis Mazmanian talks about how gut bacteria interact with the immune system to influence health and disease.
David Walt discusses his research on using fluorescent bacteria to send secret messages.
2011 Nobel Prize winner Bruce Beutler talks about his discovery of the first mammalian innate immune receptors, our first line of defense against the threat of microorganisms.
Medical entomologist Scott O'Neill explains how an intracellular bacterium could help curb the spread of dengue virus.
Cell biologist Ira Mellman discusses cancer immunotherapy at Genentech.
Changhuei Yang and Guoan Zheng talk about their inexpensive, lens-free biomedical imaging device, which could change the way we do microscopy.
Spanish chef Ferran Adrià and physicist David Weitz discuss the science of cooking.
Lora Hooper talks about the complex bacterial ecosystem in our gut and its important role in metabolism and immunity.
Baruch Fischhoff and Dietram Scheufele discuss the need for a scientific approach to the communication of science.
Structural biologist Pamela Björkman explains how engineering improved versions of naturally occurring antibodies against HIV might make them promising therapeutic agents.